The IBAL technology (Ion Biotechnology Aqueous Ligands) represents a new class of therapeutic innovation based on […]
The IBAL technology (Ion Biotechnology Aqueous Ligands) represents a new class of therapeutic innovation based on […]
Preliminary Evaluation of ION-ZC1 as a Potential Anticancer Agent In Vitro Completed in 2018 by Brooklyn […]
